Relief therapeutics « Terug naar discussie overzicht

Relief therapeutics Holding

8.269 Posts, Pagina: « 1 2 3 4 5 6 ... 285 286 287 288 289 290 291 292 293 294 295 ... 410 411 412 413 414 » | Laatste
Rotmeo
0
Volgens mij timmeren ze al behoorlijk aan de weg.... kan toch enkel gebaseerd zijn op goede uitkomst?
eric_k4
2
Tribute no. xxx to DZR

About RLF-100

RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for Aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on development of an inhaled formulation of Aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of Aviptadil.
evr68@hotmail.com
0
quote:

eric_k4 schreef op 28 januari 2021 21:18:


Tribute no. xxx to DZR

About RLF-100

RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for Aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on development of an inhaled formulation of Aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of Aviptadil.


Geweldig nieuws!
MB had je ze ook in je bezit?
Rotmeo
1
Metaphor
1
quote:

Frank312 schreef op 28 januari 2021 21:07:


KABOEM. op een goede manier.

Zoiets als Gamestop :-)
Rotmeo
0
Benieuwd waar hij op landt straks.... we hebben wel vaker een laatste moment dip gezien...
Djazz
2
Rotmeo
1
quote:

Kleintje66 schreef op 28 januari 2021 21:43:


Knettergek daar:
finance.yahoo.com/quote/GBR?p=GBR

Als we dat toch hadden geweten...pfffff
Kleintje66
0
quote:

Rotmeo schreef op 28 januari 2021 21:48:


[...]
Als we dat toch hadden geweten...pfffff

Toch eens in de gaten gaan houden welke goedkope fondsen gaan stijgen zonder aanwijsbare oorzaak. Ik denk dat degene die dit begint stinkend rijk aan het worden is terwijl anderen met dure aandelen blijven zitten. Lijkt toch wel op strafbaar handelen wat mij betreft.
Metaphor
0
[quote alias=MisterBlues id=13137663 date=202101281616]
[...]

Dat moet je eens aan de Afro-Amerikanen, Zuid-Afrikanen, andere Afrikanen, Indiërs, andere Aziaten etc. etc. vragen...
[/quote
Geen geld voor een Vaccin = Geen geld voor andere middelen vrees ik.
Echter toelating voor deze indicatie opent enorm veel andere deuren...
Ik zie het niet zo heel somber in :-) Integendeel...
M c M
0
quote:

eric_k4 schreef op 28 januari 2021 21:18:


Tribute no. xxx to DZR

About RLF-100

RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for Aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on development of an inhaled formulation of Aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of Aviptadil.


Officieel PB? Ik zie het nog niet. Koers van 0.75 naar 0.57 dollar (al is dat ook niet slecht natuurlijk)
M c M
0
8.269 Posts, Pagina: « 1 2 3 4 5 6 ... 285 286 287 288 289 290 291 292 293 294 295 ... 410 411 412 413 414 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 23 jul 2021 17:30
Koers 0,234
Verschil +0,029 (+14,15%)
Hoog 0,237
Laag 0,215
Volume 35.053.692
Volume gemiddeld 0
Volume gisteren 2.395.330

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront